Knight Therapeutics Inc (TSE:GUD)’s share price hit a new 52-week low on Monday . The stock traded as low as C$7.27 and last traded at C$7.33, with a volume of 81800 shares trading hands. The stock had previously closed at C$7.35.
Separately, Raymond James set a C$10.25 price target on Knight Therapeutics and gave the company an “outperform” rating in a report on Friday, March 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of C$10.06.
The firm has a market cap of $1.05 billion and a PE ratio of 43.39.
In other news, Director Jonathan Ross Goodman acquired 3,600 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was purchased at an average cost of C$7.38 per share, for a total transaction of C$26,568.00. Following the completion of the transaction, the director now directly owns 444,320 shares in the company, valued at C$3,279,081.60.
About Knight Therapeutics (TSE:GUD)
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
See Also: Swap
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.